Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198384 | 0.81 | MEN1 (0.40) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| Ammonia Solution, Strong SCHEMBL11682036 | 0.79 | MEN1 (0.39) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| Ammonia Solution, Strong SCHEMBL11682038 | 0.79 | MEN1 (0.39) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL421908 | 0.77 | DGAT1 (0.35) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL28160941 | 0.77 | L3MBTL1 (0.33) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL15438870 | 0.77 | ELANE (0.37) | — | |
| SCHEMBL805146 | 0.77 | TSHR (0.34) | CA12CA2L3MBTL1TDP1 | |
| Butane SCHEMBL97927 | 0.76 | MEN1 (0.36) | CYP2D6CA12CA14L3MBTL1TDP1 | |
| SCHEMBL3474238 | 0.76 | CYP2D6 (0.38) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL12861693 | 0.76 | CYP2D6 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-9469623-B2 | Preparation method for optically active bicyclic gamma-amino acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9394235-B2 | Optical resolution methods for bicyclic compounds using enzymes | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150218123-A1 | Preparation Method for Optically Active Bicyclic Gamma-Amino Acid Compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9035103-B2 | Optical resolution methods for bicyclic compounds using asymmetric catalysts | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-05-19 | — | — | US | disclosed |
| US-20150038738-A1 | Optical Resolution Methods for Bicyclic Compounds Using Enzymes | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-05 | — | — | US | disclosed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | DGAT1 4205/4885CYP2D6 1150/4885HDAC3 2239/4885 |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | OXER1, OCIAD2, AOC2 | DGAT1 160/4885CYP2D6 768/4885HDAC3 338/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | DGAT1 4033/4885CYP2D6 2562/4885HDAC3 944/4885 |
| US-20150218123-A1 | Preparation Method for Optically Active Bicyclic Gamma-Amino Acid Compound | BCAT1, BCAT2, SLC7A1 | DGAT1 3838/4885CYP2D6 1516/4885HDAC3 3872/4885 |
| US-20150038738-A1 | Optical Resolution Methods for Bicyclic Compounds Using Enzymes | BLVRB, DCXR, CYP51A1 | DGAT1 673/4885CYP2D6 222/4885HDAC3 509/4885 |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | STAT6, STAT5B, STAT5A | DGAT1 1677/4885CYP2D6 2890/4885HDAC3 282/4885 |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | DGAT1 4701/4885CYP2D6 321/4885HDAC3 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.